ASLAN Pharmaceuticals (NASDAQ:ASLN) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a research report report published on Monday, Benzinga reports. The firm currently has a $9.00 target price on the stock.

Separately, Piper Sandler reiterated an overweight rating and set a $10.00 target price (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a report on Wednesday, March 13th.

ASLAN Pharmaceuticals Stock Performance

Shares of NASDAQ:ASLN opened at $0.49 on Monday. The business’s fifty day moving average price is $0.61 and its two-hundred day moving average price is $0.76. The stock has a market cap of $8.03 million, a PE ratio of -0.18 and a beta of 1.45. ASLAN Pharmaceuticals has a one year low of $0.39 and a one year high of $4.69.

Institutional Investors Weigh In On ASLAN Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Millennium Management LLC boosted its holdings in shares of ASLAN Pharmaceuticals by 4.1% during the fourth quarter. Millennium Management LLC now owns 1,654,153 shares of the company’s stock worth $595,000 after purchasing an additional 64,784 shares during the last quarter. UBS Group AG acquired a new stake in shares of ASLAN Pharmaceuticals during the fourth quarter worth $326,000. Renaissance Technologies LLC boosted its holdings in shares of ASLAN Pharmaceuticals by 574.1% during the second quarter. Renaissance Technologies LLC now owns 475,896 shares of the company’s stock worth $236,000 after purchasing an additional 405,296 shares during the last quarter. Citigroup Inc. acquired a new stake in shares of ASLAN Pharmaceuticals during the fourth quarter worth $104,000. Finally, Bank of America Corp DE boosted its holdings in shares of ASLAN Pharmaceuticals by 34.4% during the first quarter. Bank of America Corp DE now owns 259,722 shares of the company’s stock worth $233,000 after purchasing an additional 66,544 shares during the last quarter. Institutional investors and hedge funds own 58.82% of the company’s stock.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.